department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Tukysa · pharmadog

pharmadog
drugs
Tukysa

drug

patient view →

tucatinib

Marketedupdated 2mo ago

by Seagen Inc

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Tukysa

generic

tucatinib

indication

Metastatic Colorectal Cancer

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Apr 17, 2027

284 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (14)

Apr 27, 2038method-of-use (U-3783)US 11207324
Apr 27, 2038method-of-use (U-3783)US 11207324
Apr 27, 2038method-of-use (U-3783)US 11666572
Apr 27, 2038method-of-use (U-3783)US 11666572
Apr 27, 2038method-of-use (U-3783)US 12048698
Apr 27, 2038method-of-use (U-3783)US 12048698
Mar 25, 2033method-of-use (U-2788)US 11504370
Mar 25, 2033method-of-use (U-2788)US 11504370
Oct 12, 2032formulationUS 9457093
Oct 12, 2032formulationUS 9457093
Jan 14, 2031compositionUS 86480874.5y
Jan 14, 2031compositionUS 86480874.5y
May 9, 2027formulationUS 9693989306d
May 9, 2027formulationUS 9693989306d

FDA exclusivities (6)

Jan 19, 2030ODE-422Orphan Drug (7y)3.5y
Jan 19, 2030ODE-422Orphan Drug (7y)3.5y
Apr 17, 2027ODE-309Orphan Drug (7y)284d
Apr 17, 2027ODE-309Orphan Drug (7y)284d
Jan 19, 2026I-906Indication (3y)
Jan 19, 2026I-906Indication (3y)

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Trials studying tucatinib

phase3T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trialactive not recruitingn=1,056
phase3RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positiverecruitingn=650
phase2TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancerrecruitingn=4,200
phase3A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Canceractive not recruitingn=654
phase3A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancerrecruitingn=400
phase2Tucatinib+Trastuzumab+Eribulin in HER2+ MBCrecruitingn=30
phase3A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Canceractive not recruitingn=466
phase2Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)recruitingn=720

more trials →